US6096342A
(en)
*
|
1997-03-12 |
2000-08-01 |
The Procter & Gamble Company |
Dosage forms of risedronate
|
ES2149781T3
(es)
*
|
1991-11-22 |
2000-11-16 |
Procter & Gamble Pharma |
Composiciones de risedronato de liberacion retardada.
|
US5580578A
(en)
*
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US7070806B2
(en)
|
1992-01-27 |
2006-07-04 |
Purdue Pharma Lp |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
JP2916978B2
(ja)
*
|
1993-08-25 |
1999-07-05 |
エスエス製薬株式会社 |
放出開始制御型製剤
|
US5431920A
(en)
*
|
1993-09-21 |
1995-07-11 |
Merck Frosst, Canada, Inc. |
Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
|
GB9412394D0
(en)
*
|
1994-06-21 |
1994-08-10 |
Danbiosyst Uk |
Colonic drug delivery composition
|
US5733575A
(en)
*
|
1994-10-07 |
1998-03-31 |
Bpsi Holdings, Inc. |
Enteric film coating compositions, method of coating therewith, and coated forms
|
GB9620709D0
(en)
*
|
1996-10-04 |
1996-11-20 |
Danbiosyst Uk |
Colonic delivery of weak acid drugs
|
DE19719680A1
(de)
|
1997-05-09 |
1998-11-19 |
Boehringer Mannheim Gmbh |
Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
|
TR200000111T2
(tr)
*
|
1997-06-11 |
2000-05-22 |
The Procter & Gamble Company |
Gelişmiş üst gastrointestinal traktus güvenliği için film kaplı tablet.
|
US20010031244A1
(en)
*
|
1997-06-13 |
2001-10-18 |
Chiesi Farmaceutici S.P.A. |
Pharmaceutical aerosol composition
|
US6432932B1
(en)
|
1997-07-22 |
2002-08-13 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
ES2253136T1
(es)
*
|
1997-07-22 |
2006-06-01 |
MERCK & CO. INC. |
Procedimiento para inhibir la resorcion osea.
|
US5994329A
(en)
|
1997-07-22 |
1999-11-30 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
EP0998932A1
(de)
*
|
1998-10-09 |
2000-05-10 |
Boehringer Mannheim Gmbh |
Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
|
EP0998933A1
(de)
*
|
1998-10-09 |
2000-05-10 |
Boehringer Mannheim Gmbh |
Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
|
CA2363123C
(en)
*
|
1999-02-22 |
2011-09-06 |
Kenneth Iain Cumming |
Solid oral dosage form containing an enhancer
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
US6761903B2
(en)
|
1999-06-30 |
2004-07-13 |
Lipocine, Inc. |
Clear oil-containing pharmaceutical compositions containing a therapeutic agent
|
US6248363B1
(en)
*
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
EP1064938A1
(de)
*
|
1999-06-28 |
2001-01-03 |
Sanofi-Synthelabo |
Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
|
US20030236236A1
(en)
*
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US6458383B2
(en)
|
1999-08-17 |
2002-10-01 |
Lipocine, Inc. |
Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
|
US6982281B1
(en)
*
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
US6387403B1
(en)
*
|
1999-09-15 |
2002-05-14 |
Alza Corporation |
Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
|
AR021347A1
(es)
|
1999-10-20 |
2002-07-17 |
Cipla Ltd |
Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
|
AU2127200A
(en)
*
|
1999-11-02 |
2001-05-14 |
Cipla Limited |
A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof
|
DE19954421A1
(de)
*
|
1999-11-12 |
2001-05-31 |
Lohmann Therapie Syst Lts |
Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen
|
PE20011061A1
(es)
*
|
2000-02-01 |
2001-11-20 |
Procter & Gamble |
Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
|
US6468559B1
(en)
|
2000-04-28 |
2002-10-22 |
Lipocine, Inc. |
Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
|
ES2243457T3
(es)
*
|
2001-01-23 |
2005-12-01 |
Gador S.A. |
Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma.
|
ES2268086T3
(es)
*
|
2001-05-02 |
2007-03-16 |
Novartis Ag |
Metodo de administracion de bisfosfonatos por inhalacion en el tratamiento o prevencion de la resorcion osea y la osteoporosis.
|
AU4061702A
(en)
*
|
2001-05-15 |
2003-04-03 |
Mcneil-Ppc, Inc. |
Dip coating compositions containing starch or dextrin
|
US20030070584A1
(en)
*
|
2001-05-15 |
2003-04-17 |
Cynthia Gulian |
Dip coating compositions containing cellulose ethers
|
US20030072729A1
(en)
*
|
2001-05-15 |
2003-04-17 |
Christopher Szymczak |
Simethicone as weight gain enhancer
|
US20030072731A1
(en)
*
|
2001-05-15 |
2003-04-17 |
Cynthia Gulian |
Dip coating compositions containing starch or dextrin
|
US8309118B2
(en)
*
|
2001-09-28 |
2012-11-13 |
Mcneil-Ppc, Inc. |
Film forming compositions containing sucralose
|
GB0203296D0
(en)
|
2002-02-12 |
2002-03-27 |
Glaxo Group Ltd |
Novel composition
|
CA2480814A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Merck & Co., Inc. |
Method for inhibiting bone resorption with an alendronate and vitamin d formulation
|
US20030195170A1
(en)
*
|
2002-04-11 |
2003-10-16 |
Judith Aronhime |
Novel polymorphs and pseudopolymorphs of risedronate sodium
|
BR0308901A
(pt)
*
|
2002-05-10 |
2005-01-04 |
Hoffmann La Roche |
ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
|
US8637512B2
(en)
|
2002-07-29 |
2014-01-28 |
Glaxo Group Limited |
Formulations and method of treatment
|
US7429619B2
(en)
*
|
2002-08-02 |
2008-09-30 |
Mcneil Consumer Healthcare |
Polyacrylic film forming compositions
|
US20040097468A1
(en)
*
|
2002-11-20 |
2004-05-20 |
Wimalawansa Sunil J. |
Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
|
US7115283B2
(en)
*
|
2003-05-06 |
2006-10-03 |
Access Business Group International Llc |
Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
|
US20050002996A1
(en)
*
|
2003-07-02 |
2005-01-06 |
Milan Sojka |
Sustained release compositions and controlled delivery method
|
ATE493423T1
(de)
*
|
2003-07-30 |
2011-01-15 |
Warner Chilcott Co Llc |
Verfahren zur steuerung der kristallstruktur von risedronat
|
US20060003002A1
(en)
*
|
2003-11-03 |
2006-01-05 |
Lipocine, Inc. |
Pharmaceutical compositions with synchronized solubilizer release
|
WO2005107714A2
(en)
*
|
2004-05-05 |
2005-11-17 |
Alkermes Controlled Therapeutics, Inc. |
Method of forming microparticles that include a bisphosphonate and a polymer
|
US20050261250A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Merck & Co., Inc., |
Compositions and methods for inhibiting bone resorption
|
US7645460B2
(en)
|
2004-05-24 |
2010-01-12 |
The Procter & Gamble Company |
Dosage forms of risedronate
|
US20080286359A1
(en)
|
2004-05-24 |
2008-11-20 |
Richard John Dansereau |
Low Dosage Forms Of Risedronate Or Its Salts
|
US7645459B2
(en)
|
2004-05-24 |
2010-01-12 |
The Procter & Gamble Company |
Dosage forms of bisphosphonates
|
US20080287400A1
(en)
*
|
2004-05-24 |
2008-11-20 |
Richard John Dansereau |
Low Dosage Forms Of Risedronate Or Its Salts
|
CA2566798A1
(en)
*
|
2004-05-24 |
2005-12-08 |
The Procter & Gamble Company |
Enteric solid oral dosage form of bisphosphonate containing a chelating agent
|
US8158153B2
(en)
*
|
2005-03-17 |
2012-04-17 |
Alkermes Pharma Ireland Limited |
Nanoparticulate bisphosphonate compositions
|
US20070014847A1
(en)
*
|
2005-07-05 |
2007-01-18 |
Ahmed Salah U |
Coated capsules and methods of making and using the same
|
GB2430156A
(en)
*
|
2005-09-16 |
2007-03-21 |
Selamine Ltd |
Bisphosphonate formulation
|
US7473684B2
(en)
|
2005-09-16 |
2009-01-06 |
Selamine Limited |
Bisphosphonate formulation
|
US8187639B2
(en)
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
CA2949643C
(en)
*
|
2005-09-27 |
2018-05-15 |
Tissuetech, Inc. |
Amniotic membrane preparations and purified compositions and methods of use
|
AP3071A
(en)
|
2005-11-28 |
2014-12-31 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the makingand use thereof
|
WO2007117706A2
(en)
|
2006-04-07 |
2007-10-18 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
US20080014257A1
(en)
*
|
2006-07-14 |
2008-01-17 |
Par Pharmaceutical, Inc. |
Oral dosage forms
|
ATE510538T1
(de)
|
2006-08-11 |
2011-06-15 |
Univ Johns Hopkins |
Zusammensetzungen und verfahren für nervenschutz
|
GB0616794D0
(en)
|
2006-08-24 |
2006-10-04 |
Arrow Int Ltd |
Solid dosage form
|
NZ601278A
(en)
|
2006-09-22 |
2013-09-27 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
JP2010513475A
(ja)
|
2006-12-20 |
2010-04-30 |
ランドシュタイナー サイエンティフィック エッセ アー デ シー ヴイ |
リセドロネートおよびビタミンd組成物
|
DE102007030370A1
(de)
|
2007-06-29 |
2009-01-02 |
Ratiopharm Gmbh |
Essigsäure-Solvate von Risedronat, Polymorph hiervon, deren Herstellung und Verwendung sowie pharmazeutische Zusammensetzung, enthaltend diese
|
JP5060192B2
(ja)
*
|
2007-07-18 |
2012-10-31 |
京セラドキュメントソリューションズ株式会社 |
現像装置および画像形成装置
|
CN101854933A
(zh)
|
2007-09-10 |
2010-10-06 |
钙医学公司 |
调节细胞内钙的化合物
|
EP2257220B1
(de)
*
|
2008-03-13 |
2017-06-14 |
Liebel-Flarsheim Company LLC |
Fussbetätigte multifunktionssteuerung für bildgebungssystem
|
CA2723541A1
(en)
|
2008-05-07 |
2009-11-12 |
Merrion Research Iii Limited |
Compositions of peptides and processes of preparation thereof
|
WO2010027875A2
(en)
|
2008-08-27 |
2010-03-11 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
DK2421901T3
(en)
|
2009-04-24 |
2016-01-11 |
Tissue Tech Inc |
Compositions comprising HC-HA complex, and methods of use thereof
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
WO2011120033A1
(en)
|
2010-03-26 |
2011-09-29 |
Merrion Research Iii Limited |
Pharmaceutical compositions of selective factor xa inhibitors for oral administration
|
EP2558866B1
(de)
|
2010-04-15 |
2016-08-17 |
Tracon Pharmaceuticals, Inc. |
Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
|
WO2011139765A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
AU2011261185A1
(en)
|
2010-06-03 |
2013-01-10 |
Pharmacyclics, Inc. |
The use of inhibitors of Bruton's tyrosine kinase (Btk)
|
CN103180316A
(zh)
|
2010-08-27 |
2013-06-26 |
钙医学公司 |
调节细胞内钙的化合物
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
BR112013017169A2
(pt)
|
2011-01-07 |
2016-10-04 |
Merrion Res Iii Ltd |
composições farmacêuticas de ferro para administração oral
|
KR20120105738A
(ko)
*
|
2011-03-16 |
2012-09-26 |
현대약품 주식회사 |
장용코팅된 경구용 제제
|
WO2012149486A1
(en)
|
2011-04-28 |
2012-11-01 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
US9682044B2
(en)
|
2011-06-10 |
2017-06-20 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
US9492423B2
(en)
|
2011-09-13 |
2016-11-15 |
Pharmacyclics Llc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
HUE049690T2
(hu)
|
2012-01-06 |
2020-10-28 |
Lundbeck La Jolla Research Center Inc |
Karbamátvegyületek és eljárások azok elõállítására és alkalmazására
|
JP6203816B2
(ja)
|
2012-03-29 |
2017-09-27 |
セラバイオーム,エルエルシー |
回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
|
KR20150003859A
(ko)
*
|
2012-04-23 |
2015-01-09 |
카딜라 핼쓰캐어 리미티드 |
살살레이트의 지연 방출성 약제학적 조성물
|
US9540382B2
(en)
|
2012-06-04 |
2017-01-10 |
Pharmacyclics Llc |
Crystalline forms of a Bruton's tyrosine kinase inhibitor
|
JP2015528001A
(ja)
|
2012-07-11 |
2015-09-24 |
ティッシュテック,インク. |
Hc−ha/ptx3複合体を含む組成物およびその使用方法
|
US9416141B2
(en)
|
2012-09-28 |
2016-08-16 |
University Of Washington Through Its Center For Commercialization |
Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JP6464142B2
(ja)
|
2013-03-14 |
2019-02-06 |
セラバイオーム,エルエルシー |
プロバイオティクス生物及び/又は治療剤の標的化胃腸管デリバリー
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
KR20160093675A
(ko)
|
2013-12-05 |
2016-08-08 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 키나제의 억제제
|
EP3134418A4
(de)
|
2014-04-23 |
2018-01-03 |
The Research Foundation for The State University of New York |
Schnelle und effiziente reaktion zur bioorthogonalen reaktion und borhaltige, zusammen damit nützliche heterocyclen
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
US10265384B2
(en)
|
2015-01-29 |
2019-04-23 |
Novo Nordisk A/S |
Tablets comprising GLP-1 agonist and enteric coating
|
KR102557184B1
(ko)
|
2015-02-06 |
2023-07-18 |
유니버시티 오브 워싱톤 |
감각 유모 세포 사멸을 예방 또는 치료하기 위한 화합물 및 방법
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
EA039121B1
(ru)
|
2015-02-27 |
2021-12-07 |
Куртана Фармасьютикалс, Инк. |
ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
|
RS65234B1
(sr)
|
2015-03-03 |
2024-03-29 |
Pharmacyclics Llc |
Farmaceutske formulacije inhibitora brutonove tirozin kinaze
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
CA2984480A1
(en)
|
2015-05-11 |
2016-11-17 |
Abide Therapeutics, Inc. |
Methods of treating inflammation or neuropathic pain
|
EP3297645A4
(de)
|
2015-05-20 |
2018-12-12 |
Tissuetech, Inc. |
Zusammensetzungen und verfahren zur verhinderung der proliferation und des epithelial-mesenchymalen übergangs von epithelzellen
|
BR112018003836A2
(pt)
|
2015-08-31 |
2018-12-04 |
Pharmacyclics Llc |
combinações de inibidor de btk para tratar mieloma múltiplo
|
FI3827838T3
(fi)
|
2015-12-16 |
2023-06-19 |
Walter & Eliza Hall Inst Medical Res |
Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa
|
US20190290650A1
(en)
|
2016-01-19 |
2019-09-26 |
Janssen Pharmaceutic Nv |
Formulations/compositions comprising a btk inhibitor
|
JP7109365B2
(ja)
|
2016-01-19 |
2022-07-29 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Btk阻害剤を含む製剤/組成物
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
WO2017147146A1
(en)
|
2016-02-23 |
2017-08-31 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists
|
EP3442538A4
(de)
|
2016-04-04 |
2019-11-20 |
Sinopia Biosciences, Inc. |
Behandlung von extrapyramidalem syndrom mit trapidil
|
WO2017189995A1
(en)
*
|
2016-04-28 |
2017-11-02 |
Amplipharm Pharmaceuticals, LLC |
Temozolomide powder formulation
|
US10285987B2
(en)
|
2017-04-28 |
2019-05-14 |
Amplipharm Pharmaceuticals, LLC |
Device and kit for dosing and dispensing non-liquid medicine
|
US9949967B2
(en)
|
2016-04-28 |
2018-04-24 |
Amplipharm Pharmaceuticals, LLC |
Temozolomide powder formulation
|
US10821105B2
(en)
|
2016-05-25 |
2020-11-03 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
CN109475586A
(zh)
|
2016-06-29 |
2019-03-15 |
康纳塞斯创新公司 |
脱羧的大麻树脂、其用途和制备其的方法
|
JP2019524747A
(ja)
|
2016-07-18 |
2019-09-05 |
アースローシ セラピューティクス,インク. |
痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法
|
CA3035123A1
(en)
|
2016-08-26 |
2018-03-01 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
CA3043609A1
(en)
|
2016-11-16 |
2018-05-24 |
Abide Therapeutics, Inc. |
Pharmaceutical formulations
|
EA201991086A1
(ru)
|
2016-11-16 |
2019-11-29 |
|
Кристаллические формы ингибитора magl
|
JP2020503269A
(ja)
|
2016-11-28 |
2020-01-30 |
リポカイン インコーポレーテッド |
経口ウンデカン酸テストステロン療法
|
WO2019046731A1
(en)
|
2017-09-01 |
2019-03-07 |
University Of Washington |
CRYSTALLINE FORMS OF COMPOUNDS FOR PREVENTING OR TREATING DEATH OF SENSORY CILIC CELLS
|
AU2019207880B2
(en)
|
2018-01-12 |
2024-04-11 |
Boston Scientific Scimed, Inc. |
Powder for achieving hemostasis
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
KR20200143724A
(ko)
*
|
2018-04-12 |
2020-12-24 |
비피에스아이 홀딩스, 엘엘씨. |
산성화 코팅 및 코팅된 분해 저항성 기질
|
CA3107433A1
(en)
|
2018-07-27 |
2020-01-30 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic trpv1 agonists
|
BR112021011578A2
(pt)
|
2018-12-31 |
2021-08-31 |
Biomea Fusion, Llc |
Inibidores irreversíveis de interação menina-mll
|
US20220265630A1
(en)
|
2019-03-15 |
2022-08-25 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
EP4139288A1
(de)
|
2020-04-21 |
2023-03-01 |
H. Lundbeck A/S |
Synthese eines monoacylglycerol-lipasehemmers
|
EP4263542A1
(de)
|
2020-12-16 |
2023-10-25 |
Biomea Fusion, Inc. |
Kondensierte pyrimidinverbindungen als inhibitoren der menin-mll-interaktion
|
WO2022150525A1
(en)
|
2021-01-06 |
2022-07-14 |
Awakn Life Sciences |
Mdma in the treatment of alcohol use disorder
|
CA3218884A1
(en)
|
2021-05-11 |
2022-11-17 |
David Nutt |
Therapeutic aminoindane compounds and compositions
|
AU2022283967A1
(en)
|
2021-06-03 |
2024-01-18 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
US20230120115A1
(en)
|
2021-08-11 |
2023-04-20 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
TW202313004A
(zh)
|
2021-08-20 |
2023-04-01 |
美商拜歐米富士恩股份有限公司 |
Menin-mll相互作用之不可逆抑制劑的結晶形式
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
WO2023129667A1
(en)
|
2021-12-30 |
2023-07-06 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of flt3
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
WO2024011142A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|